Kathryn C Arbour1, Laura Mezquita1, Niamh Long1, Hira Rizvi1, Edouard Auclin1, Andy Ni1, Gala Martínez-Bernal1, Roberto Ferrara1, W Victoria Lai1, Lizza E L Hendriks1, Joshua K Sabari1, Caroline Caramella1, Andrew J Plodkowski1, Darragh Halpenny1, Jamie E Chaft1, David Planchard1, Gregory J Riely1, Benjamin Besse1, Matthew D Hellmann1. 1. Matthew D. Hellmann, Parker Institute for Cancer Immunotherapy; Kathryn C. Arbour, Niamh Long, Hira Rizvi, Andy Ni, W. Victoria Lai, Joshua K. Sabari, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Kathryn C. Arbour, W. Victoria Lai, Joshua K. Sabari, Jamie E. Chaft, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Laura Mezquita, Roberto Ferrara, Lizza E.L. Hendriks, Caroline Caramella, Benjamin Besse, and David Planchard, Gustave Roussy Cancer Center, Villejuif; Edouard Auclin, Hôpital Européen Georges Pompidou; Benjamin Besse, Paris-Sud University, Le Kremlin Bicêtre, Paris, France; Gala Martínez-Bernal, Virgen del Rocío Hospital, Seville, Spain; Lizza E.L. Hendriks, Maastricht University Medical Center, Maastricht, the Netherlands.
Abstract
PURPOSE: Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy of PD-(L)1 blockade. On-treatment corticosteroids for treatment of immune-related adverse events do not seem to affect efficacy, but the potential impact of baseline corticosteroids at the time of treatment initiation is unknown. Clinical trials typically excluded patients who received baseline corticosteroids, which led us to use real-world data to examine the effect of corticosteroids at treatment initiation. METHODS: We identified patients who were PD-(L)1-naïve with advanced non-small-cell lung cancer from two institutions-Memorial Sloan Kettering Cancer Center and Gustave Roussy Cancer Center-who were treated with single-agent PD-(L)1 blockade. Clinical and pharmacy records were reviewed to identify corticosteroid use at the time of beginning anti-PD-(L)1 therapy. We performed multivariable analyses using Cox proportional hazards regression model and logistic regression. RESULTS: Ninety (14%) of 640 patients treated with single-agent PD-(L)1 blockade received corticosteroids of ≥ 10 mg of prednisone equivalent daily at the start of the PD-(L)1 blockade. Common indications for corticosteroids were dyspnea (33%), fatigue (21%), and brain metastases (19%). In both independent cohorts, Memorial Sloan Kettering Cancer Center (n = 455) and Gustave Roussy Cancer Center (n = 185), baseline corticosteroids were associated with decreased overall response rate, progression-free survival, and overall survival with PD-(L)1 blockade. In a multivariable analysis of the pooled population, adjusting for smoking history, performance status, and history of brain metastases, baseline corticosteroids remained significantly associated with decreased progression-free survival (hazard ratio, 1.3; P = .03), and overall survival (hazard ratio, 1.7; P < .001). CONCLUSION: Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non-small-cell lung cancer who were treated with PD-(L)1 blockade. Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended.
PURPOSE: Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy of PD-(L)1 blockade. On-treatment corticosteroids for treatment of immune-related adverse events do not seem to affect efficacy, but the potential impact of baseline corticosteroids at the time of treatment initiation is unknown. Clinical trials typically excluded patients who received baseline corticosteroids, which led us to use real-world data to examine the effect of corticosteroids at treatment initiation. METHODS: We identified patients who were PD-(L)1-naïve with advanced non-small-cell lung cancer from two institutions-Memorial Sloan Kettering Cancer Center and Gustave Roussy Cancer Center-who were treated with single-agent PD-(L)1 blockade. Clinical and pharmacy records were reviewed to identify corticosteroid use at the time of beginning anti-PD-(L)1 therapy. We performed multivariable analyses using Cox proportional hazards regression model and logistic regression. RESULTS: Ninety (14%) of 640 patients treated with single-agent PD-(L)1 blockade received corticosteroids of ≥ 10 mg of prednisone equivalent daily at the start of the PD-(L)1 blockade. Common indications for corticosteroids were dyspnea (33%), fatigue (21%), and brain metastases (19%). In both independent cohorts, Memorial Sloan Kettering Cancer Center (n = 455) and Gustave Roussy Cancer Center (n = 185), baseline corticosteroids were associated with decreased overall response rate, progression-free survival, and overall survival with PD-(L)1 blockade. In a multivariable analysis of the pooled population, adjusting for smoking history, performance status, and history of brain metastases, baseline corticosteroids remained significantly associated with decreased progression-free survival (hazard ratio, 1.3; P = .03), and overall survival (hazard ratio, 1.7; P < .001). CONCLUSION: Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non-small-cell lung cancer who were treated with PD-(L)1 blockade. Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended.
Authors: Daniel Dubinski; Elke Hattingen; Christian Senft; Volker Seifert; Kevin G Peters; Yvonne Reiss; Kavi Devraj; Karl H Plate Journal: J Cereb Blood Flow Metab Date: 2019-06-25 Impact factor: 6.200
Authors: Adrienne M Luoma; Shengbao Suo; Hannah L Williams; Tatyana Sharova; Keri Sullivan; Michael Manos; Peter Bowling; F Stephen Hodi; Osama Rahma; Ryan J Sullivan; Genevieve M Boland; Jonathan A Nowak; Stephanie K Dougan; Michael Dougan; Guo-Cheng Yuan; Kai W Wucherpfennig Journal: Cell Date: 2020-06-29 Impact factor: 41.582
Authors: Kevin Tyan; Joanna Baginska; Martha Brainard; Anita Giobbie-Hurder; Mariano Severgnini; Michael Manos; Rizwan Haq; Elizabeth I Buchbinder; Patrick A Ott; F Stephen Hodi; Osama E Rahma Journal: Cancer Immunol Immunother Date: 2021-01-22 Impact factor: 6.968
Authors: Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe Journal: Trends Immunol Date: 2019-04-30 Impact factor: 16.687
Authors: Kathryn C Arbour; Anh Tuan Luu; Jia Luo; Justin F Gainor; Regina Barzilay; Matthew D Hellmann; Hira Rizvi; Andrew J Plodkowski; Mustafa Sakhi; Kevin B Huang; Subba R Digumarthy; Michelle S Ginsberg; Jeffrey Girshman; Mark G Kris; Gregory J Riely; Adam Yala Journal: Cancer Discov Date: 2020-09-21 Impact factor: 39.397